XORTX THERAPEUTICS INC (XRTX) Stock Income Statement
NASDAQ:XRTX - Nasdaq - CA98420Q3061 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 4.12M | 6.05M | 10.29M | 2.56M | 1.04M | |||
| Research and Development | 183.80K | 2.42M | 6.76M | 597.50K | 207.20K | |||
| Selling, General, and Administrative Expenses | 3.82M | 3.49M | 3.47M | 1.95M | 820.00K | |||
| Operating Income | -4.12M | -6.05M | -10.29M | -2.56M | -1.04M | |||
| Interest Income/Expense | 1.08M | 3.89M | 3.50M | 2.54M | -7.30K | |||
| Other Income/Expense | -279.00K | 0.00 | -926.50K | -1.14M | -600.00 | |||
| Non Recurring Items | N/A | N/A | 0.00 | 0.00 | 91.10K | |||
| Income Before Taxes | -3.31M | -2.16M | -7.72M | -1.16M | -959.30K | |||
| Net Income | -3.31M | -2.16M | -7.72M | -1.16M | -959.30K | |||
| EBITDA | -4.00M | -5.91M | -10.23M | -2.54M | -1.03M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.15 | -1.09 | -5.22 | -1.06 | -1.30 | |||
| Statistics | ||||||||
All data in USD